SBIR/STTR Research Award

Retinal tissue derived from human pluripotent stem cells for vision restoration

Award identifier 8d38c6f00923a32a8389230ff926053a9ac74d8ab2d082ed96be473ba05f4431Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,230,814

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BioTime, Inc.
Proposal award date
2017-09-30
Contract end date
2020-05-31
UEI
JB7RMLG8U699
Solicitation number
PA18-591
Topic code
NEI

Research abstract

Abstract from the original SBIR Phase II This project will test human embryonic stem cell derivedD retinal tissue transplanted in subretinal space ofanimal models with photoreceptorPRdegeneration in a longitudinal study lasting for up tomonthsWe will use a large eye animal model of early onset RD with a Crx mutationRdy Abyssinian catsand immunodeficient rats with PR degeneration SD FoxnTg SterLavRD nudeThe immediate goal is to demonstrate the survivallaminationmaturationand structural and synaptic integration of grafts with the recipient retinaand improvement in vision bymonthsand to generate standard operating procedures for transforming such technology into therapy to treat blindness caused by PR deathThe overarching goal is to evaluate this technology in pilot clinical trials in patients with retinitis pigmentosaRPan orphan disease with fast track FDA approvalBlindness is a major health concern among Americansaffecting quality of life and with a high financial and heavy emotional burdenThe two major retinal diseases associated with photoreceptor degeneration are RP and dry age related macular degenerationAMDThere is a critical and urgent need to find new treatments of RP and AMD based on photoreceptor replacementThe research in the pastyears indicates that a piece of degenerating mammalian retina can be replaced with healthy fetal retinal tissuewhich can improve visionThe research shows that grafted fetal retina will complete differentiationsynapse on the recipient retinal ganglion cell neuronsand re establish connectivity with the visual cortexHuman fetal derived retinal tissue supply is very limitedand its clinical use in therapy is ethically not acceptableBioTime hypothesizes thatweek old human embryonic stem cell derivedD retinal tissue will integrate structurally and synaptically into the degenerating recipient retina and improve vision in animals with advanced RDWe predict that demonstrating positive therapeutic impact of hESCD retinal tissue grafting in alarge eyeanimal model with RD will enable us to move this technology to pilot clinical trials in RP patientsWe have already developed hESCD retinal tissue and demonstrated that it carries a layer of RPEPRssecond order neurons and ganglion cellsis capable of axonogenesissynaptogenesis and becomes progressively electrically activeWe also reported that it improves vision in a rat animal model with RP and blindness and activates superior colliculusWe propose to do in vivo testing in alarge eyeanimal model of RDRdy catswith blindnessand in a large cohort of SD FoxnTg SterLavRD nuderats with RD to statistically evaluate the feasibility of this therapy in RP patientsIn AimBioTimewe will scale up production of hESCD retinal tissue from cGMP grade hESCs andevaluate several lots using FDA criteriaIn AimUCIwe will do subretinal grafting into blind rats and evaluate vision improvements and grafthost connectivityIn AimMSUwe will do subretinal grafting into Rdycats and also evaluate vision improvements andgraft host connectivityThe results and procedures will be integrated into clinical protocols to enable clinical trials of blindness caused by PR degeneration Narrative from original Phase II SBIR Blindness is a major health fear among Americansand is a costly burden on our societyWe will test human embryonic stem cell derivedDimensional retinal tissueretinal patch grown as neural retinaRPE togetherin the subretinal space of a large eye animal model of RDAbyssinian cats with Crx mutation Rdyand blind immunodeficient rats with photoreceptor degenerationThe immediate goal is to demonstrate the survivalstructural and synaptic integration of grafts in the subretinal spaceand improvement in vision in two models of human RDThe ultimate goal is to delineate standard operating procedures for transforming such technology into cell therapy to treat blindness caused by PR degeneration and to test retinal patch technology in pilot clinical trials in patients with RPan orphan class disease with fast FDA approval

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2004–2018). Reported award amounts total $3,762,961. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.